Emergence of pipeline combination therapies and VEGF inhibitors will trigger growth in the wet AMD market.
By Hardik Patel, Lead Analyst
14 April 2016
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
The launch of anti-platelet-derived growth factor (PDGF) therapy Fovista (pegpleranib; Ophthotech/Novartis), topical treatment squalamine (Ohr Pharmaceutical), and pipeline vascular endothelial growth factor (VEGF) inhibitors brolucizumab (Novartis) and abicipar pegol (Allergan/Molecular Partners) will prompt a sizable increase in the wet AMD market. Together, these four pipeline drugs are forecast to account for 57% of total market sales in the US and five major EU markets by 2023. Because both Fovista and squalamine will be utilized as add-on treatments to standard treatment with VEGF inhibitors, their uptake will result in direct growth of the overall market. In contrast, brolucizumab and abicipar pegol are each being trialed in bimonthly and quarterly dosing regimens, and will therefore be positioned as more convenient alternatives to currently marketed treatments.
Wet AMD market share in the US and five major EU markets, by drug status ($m), 2018–23
|Source: Datamonitor Healthcare|
This is excerpted from Datamonitor Healthcare’s Wet Age-Related Macular Degeneration: Forecast – exploring the sales dynamics between VEGF inhibitors used in the treatment of wet AMD as well as the impact of new add-on treatments for the disease.
Get your free demo today – simply fill in the form to the right.